Search research articles
Contact Us
Filters
Showing results (61-70 of 125) with videos related to
Page
of 13
Sort By:
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
Anne Tierens, Tracy L Stockley, Clinton Campbell, et al.
Oncotarget
|
September 1, 2016
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells
Sina Oppermann, Avery J Lam, Stephanie Tung, et al.
Elife
|
January 25, 2020
The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells
Xiaoke Chi, Dang Nguyen, James M Pemberton, et al.
European Journal of Haematology
|
June 11, 2015
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
Han-Xin Lin, Jenny Sjaarda, Jocob Dyck, et al.
American Journal of Blood Research
|
August 15, 2017
Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines
Joseph M Brandwein, Nancy Zhu, Rajat Kumar, et al.
Leukemia & Lymphoma
|
October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Stem Cells (Dayton, Ohio)
|
March 13, 2015
Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations
Kyle R Salci, Jong-Hee Lee, Sarah Laronde, et al.
Leukemia Research
|
April 15, 2008
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline
Richard A Wells, Brian Leber, Rena Buckstein, et al.
British Journal of Haematology
|
September 4, 2008
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro, Brian Leber, Mitchell Smith, et al.
Blood
|
June 15, 2016
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Sina Oppermann, Jarkko Ylanko, Yonghong Shi, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 125) with videos related to
Sort By:
Page
of 13
Current Oncology (Toronto, Ont.)
|
April 3, 2021
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario
Anne Tierens, Tracy L Stockley, Clinton Campbell, et al.
Oncotarget
|
September 1, 2016
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells
Sina Oppermann, Avery J Lam, Stephanie Tung, et al.
Elife
|
January 25, 2020
The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells
Xiaoke Chi, Dang Nguyen, James M Pemberton, et al.
European Journal of Haematology
|
June 11, 2015
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
Han-Xin Lin, Jenny Sjaarda, Jocob Dyck, et al.
American Journal of Blood Research
|
August 15, 2017
Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines
Joseph M Brandwein, Nancy Zhu, Rajat Kumar, et al.
Leukemia & Lymphoma
|
October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Stem Cells (Dayton, Ohio)
|
March 13, 2015
Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations
Kyle R Salci, Jong-Hee Lee, Sarah Laronde, et al.
Leukemia Research
|
April 15, 2008
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline
Richard A Wells, Brian Leber, Rena Buckstein, et al.
British Journal of Haematology
|
September 4, 2008
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro, Brian Leber, Mitchell Smith, et al.
Blood
|
June 15, 2016
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
Sina Oppermann, Jarkko Ylanko, Yonghong Shi, et al.
Page
of 13